The analogous gatekeeper position on ALK, L1196, is similarly found to be mutated in ALK fusion-positive lung cancer at the time of resistance to crizotinib and in resistant cell line models, as are several other amino acids for which mutation also reduces the ability of the drug to inhibit the kinase [12], [13], [14], [15], [16]. This evidence concerns the gene ALK and lung carcinoma.